Arkolith/Insider Trading/SYRE/Form 4

Burrows Scott L

Chief Financial OfficerSpyre Therapeutics, Inc. (SYRE) · full profile →Form 4 · filed Jun 27, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.3M
Net Open-Market Flow
-$1.3M
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 25, 2026Option exercise(M)15K$14.50$218K113K
Jun 25, 2026Sell(S)5K$87.12$436K108K
Jun 25, 2026Sell(S)10K$87.14$871K98K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 25, 2026Option exercise(M)15K—$0360K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001853327-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML